SCHEMBL24150229

SCHEMBL24150229

C=CC(=O)Nc1cc(C#N)cc(-c2ccc3cncnc3c2)c1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PLCG1 P19174 1/20 0.44
▸ BTK Q06187 3/20 0.43
▸ CCNA2 P20248 1/20 0.41
▸ CDK2 P24941 1/20 0.41
▸ CDK7 P50613 1/20 0.41
▸ CCNH P51946 1/20 0.41
▸ MNAT1 P51948 1/20 0.41
▸ JAK3 P52333 1/20 0.40
▸ IMPDH2 P12268 1/20 0.38
▸ PIK3CD O00329 2/20 0.38
▸ FYN P06241 2/20 0.37
▸ SRC P12931 2/20 0.37
▸ VCP P55072 1/20 0.37
▸ CCNK O75909 1/20 0.36
▸ CDK12 Q9NYV4 1/20 0.36
▸ BAZ1A Q9NRL2 1/20 0.36
▸ EGFR P00533 1/20 0.36
▸ CTSC P53634 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30191022 0.86 BTK (0.46) PLCG1BTKCCNA2CDK2CDK7
SCHEMBL24150231 0.86 BTK (0.46) PLCG1BTKCCNA2CDK2CDK7
SCHEMBL30190618 0.84 MAP4K4 (0.44) BTKCCNA2CDK2CDK7CCNH
SCHEMBL24150841 0.84 MAP4K4 (0.44) BTKCCNA2CDK2CDK7CCNH
SCHEMBL24151660 0.82 JAK3 (0.58) PLCG1BTKJAK3IMPDH2PIK3CD
SCHEMBL30190528 0.82 JAK3 (0.58) PLCG1BTKJAK3IMPDH2PIK3CD
SCHEMBL4593930 0.78 IMPDH2 (0.57) JAK3IMPDH2FYNSRCVCP
SCHEMBL24150335 0.76 JAK3 (0.47) PLCG1BTKJAK3IMPDH2PIK3CD
SCHEMBL19877613 0.75 PLCG1 (0.55) PLCG1BTKJAK3PIK3CDEGFR
SCHEMBL19877668 0.73 PLCG1 (0.54) PLCG1BTKJAK3EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11926632-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2024-03-12 — — US disclosed
US-20230046427-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. 2023-02-16 — — US disclosed
US-20230046427-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. 2023-02-16 — — US disclosed
WO-2021262596-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION PMV PHARMACEUTICALS, INC. (US) 2021-12-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230046427-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION TP53, TP53BP1, HRAS PLCG1 2034/4885BTK 4194/4885CCNA2 295/4885
US-11926632-B2 Methods and compounds for restoring mutant p53 function TP53, TP53BP1, HRAS PLCG1 2034/4885BTK 4194/4885CCNA2 295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback